BI Asset Management Fondsmaeglerselskab A S Sells 18,895 Shares of Edwards Lifesciences Corporation $EW

BI Asset Management Fondsmaeglerselskab A S decreased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 37.8% during the first quarter, HoldingsChannel reports. The institutional investor owned 31,111 shares of the medical research company’s stock after selling 18,895 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Edwards Lifesciences were worth $2,491,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. JPL Wealth Management LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at approximately $25,000. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth $26,000. Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $27,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $28,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $28,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $86.98 on Wednesday. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $50.08 billion, a PE ratio of 46.27, a price-to-earnings-growth ratio of 2.15 and a beta of 0.87. The firm’s 50 day moving average price is $83.70 and its 200-day moving average price is $83.16. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $89.60.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. During the same period in the previous year, the business posted $0.64 earnings per share. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. The trade was a 3.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the completion of the sale, the vice president owned 33,934 shares of the company’s stock, valued at $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 81,038 shares of company stock worth $6,683,255. 0.31% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on EW shares. Robert W. Baird boosted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Mizuho set a $95.00 price target on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Finally, Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a research report on Wednesday, April 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $95.96.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.